公开(公告)号：US20240190860A1

公开(公告)日：2024-06-13

申请号：US18551942

申请日：2021-03-24

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Gabriele AMARI ,  Elisabetta ARMANI ,  Mafalda PAGANO ,  Marta GIULIANI ,  Luca RAVEGLIA ,  Claudia BEATO

IPC: C07D417/14 ,  A61K31/517 ,  C07D401/04 ,  C07D413/14

CPC classification number: C07D417/14 ,  A61K31/517 ,  C07D401/04 ,  C07D413/14

Abstract: The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are 8-cyclo-substituted quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.

公开(公告)号：US20170145004A1

公开(公告)日：2017-05-25

申请号：US15316312

申请日：2014-06-04

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Gabriele AMARI ,  Elisabetta ARMANI ,  Mauro RICCABONI ,  Charles BAKER-GLENN

IPC: C07D453/02 ,  A61K9/00 ,  A61K31/444

CPC classification number: C07D453/02 ,  A61K9/0073 ,  A61K31/444 ,  C07D453/00

Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

公开(公告)号：US20250051340A1

公开(公告)日：2025-02-13

申请号：US18720120

申请日：2022-12-21

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Gabriele AMARI ,  Carmelida CAPALDI ,  Elisabetta ARMANI

IPC: C07D487/04 ,  A61K31/519 ,  A61P11/00 ,  C07C65/11

Abstract: The present invention generally relates to a novel triazolone derivative salt particularly useful as neutrophil elastase inhibitor and to its use as a medicament. The present invention also relates to pharmaceutical compositions comprising the novel triazolone derivative salt and one or more pharmaceutically acceptable carriers and/or excipients thereof and to their use as medicament.

公开(公告)号：US20230250093A1

公开(公告)日：2023-08-10

申请号：US18015767

申请日：2021-07-15

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Elisabetta ARMANI ,  Gabriele AMARI ,  Andrea RIZZI ,  Mafalda PAGANO ,  Luca RAVEGLIA ,  Claudia BEATO

IPC: C07D413/04 ,  C07D401/04 ,  C07D413/14 ,  C07D409/04 ,  C07D417/14 ,  C07D249/06 ,  C07D417/04 ,  C07D231/40 ,  C07D333/36

CPC classification number: C07D413/04 ,  C07D401/04 ,  C07D413/14 ,  C07D409/04 ,  C07D417/14 ,  C07D249/06 ,  C07D417/04 ,  C07D231/40 ,  C07D333/36

Abstract: The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.

公开(公告)号：US20150352091A1

公开(公告)日：2015-12-10

申请号：US14723964

申请日：2015-05-28

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Elisabetta ARMANI ,  Gabriele AMARI ,  Carmelida CAPALDI ,  Wesley BLACKABY ,  Ian LINNEY ,  Hervé VAN DE POËL ,  Charles BAKER-GLENN ,  Naimisha TRIVEDI

IPC: A61K31/444 ,  A61K31/4436 ,  C07D409/12 ,  A61K31/4545 ,  C07D453/02 ,  C07D409/14

CPC classification number: A61K31/444 ,  A61K31/4436 ,  A61K31/4545 ,  C07D409/12 ,  C07D409/14 ,  C07D453/02

Abstract: Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.

Abstract translation: 式（I）化合物（本文定义）均为磷酸二酯酶4（PDE4）酶抑制剂和毒蕈碱M3受体拮抗剂，可用于预防和/或治疗呼吸道疾病。

公开(公告)号：US20250066341A1

公开(公告)日：2025-02-27

申请号：US18723049

申请日：2022-12-21

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Elisabetta ARMANI ,  Gabriele AMARI ,  Mafalda PAGANO ,  Marta GIULIANI

IPC: C07D413/14 ,  A61K31/415 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  C07D261/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.

公开(公告)号：US20230061417A1

公开(公告)日：2023-03-02

申请号：US17784551

申请日：2020-12-10

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Gabriele AMARI ,  Elisabetta ARMANI ,  Mafalda PAGANO ,  Luca RAVEGLIA

IPC: C07D495/04

Abstract: The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are thienopyrimidine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.

公开(公告)号：US20160346268A1

公开(公告)日：2016-12-01

申请号：US15168425

申请日：2016-05-31

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Gabriele AMARI ,  Elisabetta Armani ,  Wesley Blackaby ,  Herve Van De Poeol ,  Charles Baker-Glenn ,  Naimisha Trivedi

IPC: A61K31/4545 ,  C07D453/02 ,  A61K31/444 ,  A61K31/46 ,  A61K31/4436 ,  A61K31/496 ,  C07D451/02 ,  C07D409/14 ,  A61K31/4439

CPC classification number: A61K31/4545 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/46 ,  A61K31/496 ,  C07D409/14 ,  C07D451/02 ,  C07D453/02

Abstract: Compounds of formula (I) defined herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratrory tract.

Abstract translation: 本文定义的式（I）化合物均为磷酸二酯酶4（PDE4）酶抑制剂和毒蕈碱M3受体拮抗剂，可用于治疗呼吸道疾病。

公开(公告)号：US20160326147A1

公开(公告)日：2016-11-10

申请号：US15148225

申请日：2016-05-06

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Elisabetta ARMANI ,  Gabriele AMARI ,  Wesley BLACKABY ,  Herve VAN DE POEL ,  Charles BAKER-GLENN ,  Naimisha TRIVEDI

IPC: C07D409/12 ,  C07D409/14 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  C07D453/02 ,  A61K31/439

CPC classification number: C07D409/12 ,  A61K31/439 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  C07D409/14 ,  C07D453/02 ,  C07D471/08

Abstract: Compounds of formula (I) are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Abstract translation: 式（I）化合物既是磷酸二酯酶4（PDE4）酶抑制剂和毒蕈碱M3受体拮抗剂，也可用于预防和/或治疗以气道阻塞为特征的呼吸道疾病。

公开(公告)号：US20150018321A1

公开(公告)日：2015-01-15

申请号：US14496136

申请日：2014-09-25

Applicant: Chiesi Farmaceutici S.p.A.

Inventor： Maurizio DELCANALE ,  Elisabetta ARMANI ,  Gabriele AMARI

IPC: C07D213/79 ,  A61K31/44 ,  C07D213/38 ,  C07D401/12 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/4439 ,  A61K31/5377 ,  C07D405/12 ,  A61K31/4433 ,  A61K31/4709 ,  C07D473/08 ,  A61K31/522 ,  A61K31/538 ,  A61K45/06 ,  C07D213/80 ,  C07D213/30

CPC classification number: C07D213/30 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/4709 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/538 ,  A61K45/06 ,  C07D213/38 ,  C07D213/61 ,  C07D213/79 ,  C07D213/80 ,  C07D213/89 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D473/04 ,  C07D473/08

Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.